Sun Pharma Company Launches COVID-19 Drug Favipiravir In India
Favipiravir was once introduced underneath the emblem FluGuard at Rs 35 in step with pill. (Representational)
New Delhi:
Solar Pharmaceutical Industries has stated it has introduced Favipiravir (200 mg) in India underneath the emblem FluGuard at a cheap worth of Rs 35 in step with pill for the remedy of gentle to average instances of COVID-19.
Favipiravir is the one oral anti-viral remedy authorized within the nation for the possible remedy of sufferers with gentle to average COVID-19 illness.
With over 50,000 COVID-19 instances being reported day by day in India, there may be an pressing want to supply extra remedy choices to healthcare execs, stated Kirti Ganorkar, CEO of India Industry at Solar Pharma.
“We’re launching FluGuard at a cheap worth to make the drug available to increasingly sufferers, thereby lowering their monetary burden. That is consistent with our steady efforts to enhance India”s pandemic reaction,” he stated in a remark.
The corporate will paintings carefully with the federal government and clinical neighborhood to verify the supply of FluGuard to sufferers around the nation. The shares of FluGuard might be to be had available in the market this week.
Solar Pharma is the sector’s fourth-largest speciality generic pharmaceutical corporate and India’s most sensible pharmaceutical corporate.
Handing over merchandise for patrons and sufferers in over 100 international locations, its international presence is supported by means of production amenities unfold throughout six continents which can be authorized by means of a couple of regulatory companies.
